3 Small-Cap Biotechnology Stocks Making Big Moves
During the past few weeks, investors have seen a tremendous rally in the biotechnology industry. Many stocks have been participating in the rally, but there have been a few that are especially standing out because of performance and/or new announcements.
Celldex Therapeutics (NASDAQ:CLDX) appears to have traded into another stratosphere. Since September 20, the stock has appreciated by more than 25 percent. With a lot of positive press coming out about the company’s pipeline, investors appear to be big believers in the company’s eventual ability to treat a variety of cancer indications. Of particular importance is CDX-011, an antibody-drug conjugate that targets glycoprotein NMB (GPNMB). GPNMB is a protein overexpressed by multiple tumor types, including breast cancer and melanoma. In late 2012, the company completed a Phase 2 EMERGE study in metastatic breast cancer. The final results supported overall survival benefit in patients with high GPNMB expression.
On September 23, analyst Howard Liang from Leerink Swann raised his price target for Celldex to $45. Mr. Liang expects positive updates from the company at the upcoming Society for Immunotherapy of Cancer meeting on November 7. While Celldex appears to have some incredible trading momentum, investors may want to be wary of the current market capitalization, which values the company at over $3 billion. Investors looking for a cheaper play in the breast cancer space may want to consider a smaller competitor called Medifocus (OTC:MDFZF).
Medifocus develops and commercializes minimally invasive treatment systems used in the treatment of cancerous and benign tumors, and enlarged prostate. Of particular importance to breast cancer patients is Medifocus’s APA-1000 system, which has already received FDA approval for use with radiation therapy. The system has also received the green light from the FDA to begin the Phase 3 trial for breast cancer treatment in Canada and the United States.